Financial Analysis: Adagio Medical (ADGM) & Its Rivals

Adagio Medical (NASDAQ:ADGM) is one of 142 public companies in the “MED INSTRUMENTS” industry, but how does it weigh in compared to its competitors? We will compare Adagio Medical to related companies based on the strength of its dividends, earnings, valuation, profitability, risk, analyst recommendations and institutional ownership.

Risk & Volatility

Adagio Medical has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500. Comparatively, Adagio Medical’s competitors have a beta of 1.88, suggesting that their average share price is 88% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Adagio Medical and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagio Medical	1	0	0	0	1.00
Adagio Medical Competitors	1250	3834	7162	271	2.52

As a group, “MED INSTRUMENTS” companies have a potential upside of 7.75%. Given Adagio Medical’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Adagio Medical has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Adagio Medical and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Adagio Medical	$600,000.00	-$75.04 million	-0.55
Adagio Medical Competitors	$1.75 billion	$196.07 million	5.66

Adagio Medical’s competitors have higher revenue and earnings than Adagio Medical. Adagio Medical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Adagio Medical and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adagio Medical	N/A	-791.01%	-199.58%
Adagio Medical Competitors	-482.31%	-113.49%	-21.33%

Institutional and Insider Ownership

48.1% of Adagio Medical shares are owned by institutional investors. Comparatively, 54.1% of shares of all “MED INSTRUMENTS” companies are owned by institutional investors. 5.2% of Adagio Medical shares are owned by insiders. Comparatively, 14.1% of shares of all “MED INSTRUMENTS” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Adagio Medical competitors beat Adagio Medical on 12 of the 13 factors compared.

Adagio Medical Company Profile

Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company’s product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. The company is based in Laguna Hills, California.